EPI-326 is a tissue-selective bispecific antibody for EGFR-driven cancers that spares healthy tissue and degrades wildtype and mutant EGFR in tumors, independent of mutations. EPI-326 holds promise to address significant unmet needs in multiple types of cancer, including non-small cell lung cancer.
